Company profile
ADC THERAPEUTICS SA
NYSE:ADCTBiotechnology: Pharmaceutical Preparations
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ZYNLONTA | approved | — | 0 | — |
| LONCASTUXIMAB TESIRINE | phase3 | — | 11 | active |
| CAMIDANLUMAB TESIRINE | phase2 | — | 4 | completed, terminated |
| MIPASETAMAB UZOPTIRINE | phase1 | — | 2 | terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (19)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05144009 | phase2 | terminated | 2022-06-21 | 2024-01-22 | ADC Therapeutics S.A. | A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) |
| NCT05389462 | phase1 | terminated | 2022-07-13 | 2025-04-17 | ADC Therapeutics S.A. | A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors |
| NCT05660395 | phase1 | terminated | 2023-07-28 | 2026-06-25 | ADC Therapeutics S.A. | A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10) |
| NCT04970901 | phase1 | active_not_recruiting | 2022-06-17 | 2027-03-31 | ADC Therapeutics S.A. | A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) |
| NCT04972981 | phase1 | completed | 2021-09-09 | 2024-09-13 | ADC Therapeutics S.A. | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 761196 | 2021-04-23 | BLA | ADC THERAPEUTICS SA | |||||
Loading… | ||||||||